Kymera Therapeutics to Participate in Upcoming March Investor Conferences
02 March 2022 - 11:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, today
announced that the Company will participate in the following
upcoming virtual investor conferences:
- Cowen & Co. 42nd Annual Health
Care Conference 2022: Fireside Chat with Nello Mainolfi, PhD,
Co-Founder, President and CEO on March 8th at 9:50 a.m.
ET
- Guggenheim Healthcare Talks |
Targeted Protein Degradation Day: Fireside Chat with Nello
Mainolfi, PhD, Co-Founder, President and CEO on March 16th at
8:00a.m. ET
Presentation webcasts will be available under
"Events and Presentations" in the Investors section of the
Company's website at www.kymeratx.com. Archived webcast replays
will be available on the website for approximately 90
days.
About Kymera
Therapeutics Kymera is a biopharmaceutical
company pioneering the field of targeted protein degradation, a
transformative approach to address disease targets and pathways
inaccessible with conventional therapeutics. Kymera’s Pegasus™
platform is a powerful drug discovery engine, advancing novel small
molecule therapies that harness the body’s innate protein recycling
machinery to degrade dysregulated, disease-causing proteins. With a
focus on undrugged nodes in validated pathways, Kymera is advancing
a pipeline of novel therapeutics designed to address the most
intractable of pathways and provide new treatments for patients.
Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within
the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to
treat patients with a broad range of immune-inflammatory diseases,
hematologic malignancies, and solid tumors. For more information,
visit www.kymeratx.com.
Investor Contact: Bruce
Jacobs Chief Financial
Officer investors@kymeratx.com 857-285-5300
Chris Brinzey Managing Director,
Westwicke chris.brinzey@westwicke.com 339-970-2843
Media Contact: Tyler
Gagnon Director, Corporate
Communications tgagnon@kymeratx.com 508-904-944
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024